Allogene Therapeutics to Host Events at American Society of Hematology Annual Meeting 2026 Highlighting the Potential of Allogeneic CAR T to Expand Patient Access
Allogene Therapeutics announced its participation in the 68th ASH Annual Meeting in New Orleans, where it will present new market research on barriers to CAR T access and showcase its pivotal ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) as MRD-guided first-line consolidation therapy for large B-cell lymphoma. The company aims to expand patient access to allogeneic CAR T through earlier treatment intervention and community-based delivery models.



